Antimalarial Synergy of Cysteine and Aspartic Protease Inhibitors
- 1 September 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (9) , 2254-2258
- https://doi.org/10.1128/aac.42.9.2254
Abstract
It has been proposed that the Plasmodium falciparumcysteine protease falcipain and aspartic proteases plasmepsin I and plasmepsin II act cooperatively to hydrolyze hemoglobin as a source of amino acids for erythrocytic parasites. Inhibitors of each of these proteases have potent antimalarial effects. We have now evaluated the antimalarial effects of combinations of cysteine and aspartic protease inhibitors. When incubated with cultured P. falciparumparasites, cysteine and aspartic protease inhibitors exhibited synergistic effects in blocking parasite metabolism and development. The inhibitors also demonstrated apparent synergistic inhibition of plasmodial hemoglobin degradation both in culture and in a murine malaria model. When evaluated for the treatment of murine malaria, a combination of cysteine and aspartic protease inhibitors was much more effective than higher concentrations of either compound used alone. These results support a model whereby plasmodial cysteine and aspartic proteases participate in the degradation of hemoglobin, and they suggest that combination antimalarial therapy with inhibitors of the two classes of proteases is worthy of further study.Keywords
This publication has 27 references indexed in Scilit:
- HEMOGLOBIN METABOLISM IN THE MALARIA PARASITEPLASMODIUM FALCIPARUMAnnual Review of Microbiology, 1997
- Expression and Characterisation of Plasmepsin I from Plasmodium falciparumEuropean Journal of Biochemistry, 1997
- Hemoglobin catabolism and iron utilization by malaria parasitesMolecular and Biochemical Parasitology, 1996
- Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway.Journal of Clinical Investigation, 1994
- Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria.Journal of Clinical Investigation, 1993
- Plasmodium falciparum: Differential Sensitivity In Vitro to E‐64 (Cysteine Protease Inhibitor) and Pepstatin A (Aspartyl Protease Inhibitor)The Journal of Protozoology, 1992
- Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase.Journal of Clinical Investigation, 1991
- Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease.The Journal of Experimental Medicine, 1991
- A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum.Journal of Clinical Investigation, 1988
- Human Malaria Parasites in Continuous CultureScience, 1976